The Growth Investor Daily Brief
Get the latest updates on U.S. startups securing Series C to IPO funding, featuring key deals, top investors, and emerging industries shaping the future.
OneRail, Tenstorrent, and Maze Therapeutics: Series C+ Funding and Future Plans
Michelle welcomes listeners to the latest episode of The Growth Investor Daily Brief, diving into recent Series C+ funding updates. The episode covers OneRail's efforts in optimizing last-mile delivery and their funding plans, as well as Tenstorrent's Series D success in the AI chip sector. Additionally, Maze Therapeutics' Series D financing and their future strategic plans are discussed. The episode wraps up with investor insights, providing listeners with essential information to stay informed about the evolving investment landscape.
Key Points
- OneRail secured $42 million in Series C funding to enhance its last-mile delivery platform, addressing the growing demand for efficient logistics solutions in the booming e-commerce sector.
- Tenstorrent raised $693 million in Series D funding, positioning itself as a flexible and cost-effective alternative to Nvidia in the AI chip market by leveraging open-source technology.
- Maze Therapeutics closed a $115 million Series D round to advance its precision medicine programs targeting renal and metabolic diseases, utilizing genetic insights to develop targeted therapies.
Speakers
Michelle
Host • 100%
Chapters
| 0:00 | |
| 0:13 | |
| 0:39 | |
| 1:21 | |
| 2:22 | |
| 5:14 |
Transcript
Loading transcript...
- / -